LG Chem and LabGenius Partner for AI Cancer Drug Discovery

South Korean firm LG Chem and UK-based LabGenius have launched a multi-year research partnership to develop advanced cancer treatments ^[1]. The collaboration focuses on creating next-generation multispecific antibodies using artificial intelligence ^[2]. By employing these digital tools, the companies aim to reduce the standard five-year drug discovery timeline to just 30 months ^[3].

LabGenius will utilize its proprietary machine-learning platform, known as EVA, to design and engineer antibodies that target tumors more precisely ^[1]. This approach helps identify lead molecules that may minimize toxicity for patients during immunotherapy ^[2]. LG Chem holds an option to license the resulting antibody candidates for further clinical development and global commercialization ^[1][3].

This agreement reflects a broader trend of major pharmaceutical players adopting AI to streamline research and development ^[2]. LG Chem intends to strengthen its oncology pipeline through this partnership while modernizing its discovery processes ^[1]. Both firms will combine their expertise to address unmet needs in the global cancer treatment market ^[3].